Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07225686 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy

Name: Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy — clinical trial record (NCT07225686)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: MARITIME-OSA-1

StatusRecruiting

PhasePhase 3

SponsorAmgen

Started2025-12-19

View on ClinicalTrials.gov ↗

This Phase 3 clinical trial is designed to evaluate the efficacy and safety of maridebart cafraglutide compared to placebo over a 52-week period in adults with obstructive sleep apnea (OSA) who are receiving positive airway pressure (PAP) therapy and are living with overweight or obesity.

Amendment history 7 changes detected by DataLookout

2026-08-05

Primary endpoint(s) modified

WasChange in AHI from baseline at week 52

NowChange in Apnea-Hypopnea Index (AHI) from baseline at week 52

2026-06-13

Trial sites expanded: 56 → 60 locations

2026-05-23

Trial sites expanded: 53 → 56 locations

2026-05-06

Trial sites expanded: 47 → 51 locations

2026-04-10

Trial sites expanded: 37 → 43 locations

2026-04-03

Trial sites expanded: 33 → 37 locations

2026-03-31

Trial sites expanded: 28 → 33 locations

Trial Details

NCT Number	NCT07225686
Lead Sponsor	Amgen
Conditions	Obesity, Obstructive Sleep Apnea
Enrollment	250 participants
Start Date	2025-12-19
Primary Completion	2027-09-29 (estimated)
Study Completion	2028-09-13 (estimated)
Updated on ClinicalTrials.gov	2026-08-04